Belite Bio
BLTE
7 hedge funds and large institutions have $3.17M invested in Belite Bio in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
17% more funds holding
Funds holding: 6 → 7 (+1)
3.73% less ownership
Funds ownership: 4.12% → 0.39% (-3.7%)
79% less capital invested
Capital invested by funds: $14.9M → $3.17M (-$11.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$168K |
| 2 |
State Street
Boston,
Massachusetts
|
+$89.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$14.6K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$13.2K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWS
Atria Wealth Solutions
New York
|
-$18.6M |
| 2 |
AC
Armistice Capital
New York
|
-$3.01M |
| 3 |
BlackRock
New York
|
-$13.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AWS
1
Atria Wealth Solutions
New York
| $2.36M | -$18.6M | -740,479 | -91% |
|
|
2
State Street
Boston,
Massachusetts
| $536K | +$89.7K | +3,580 | +27% |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $212K | +$168K | +6,700 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $28.1K | +$14.6K | +583 | +194% |
|
|
5
Qube Research & Technologies (QRT)
London,
United Kingdom
| $16.6K | +$13.2K | +525 | New |
|
6
Morgan Stanley
New York
| $13.9K | – | – | – |
|
|
7
Bank of America
Charlotte,
North Carolina
| $2.01K | +$1.58K | +63 | New |
|
|
AC
8
Armistice Capital
New York
| – | -$3.01M | -210,915 | Closed |
|
|
9
BlackRock
New York
| – | -$13.8K | -966 | Closed |
|
BLTE Hedge Fund Activity: Q3 2023 in Review
7 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Belite Bio (BLTE) for Q3 2023, worth a combined $3.17M — down 79% from $14.9M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BLTE positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $168K. The largest seller was Atria Wealth Solutions, cutting an estimated $18.6M.
- 7 institutional investors held Belite Bio (BLTE) as of Q3 2023, up from 6 in Q2 2023.
- Funds reported $3.17M of Belite Bio stock for Q3 2023, down 79% quarter-over-quarter.
- 3 funds opened new Belite Bio positions in Q3 2023 and 2 closed out, a net change of +1 holder.
- The largest Belite Bio buyer in Q3 2023 was Geode Capital Management, an estimated $168K added.
- The largest Belite Bio seller in Q3 2023 was Atria Wealth Solutions, an estimated $18.6M sold.
Based on aggregated 13F filings for Q3 2023.